Bruce N. Cronstein, Joseph R. Bertino
Springer Science & Business Media, 2000 - Medical - 139 pages
This book provides multidisciplinary reviews of the mechanism of action and uses of methotrexate in the treatment of cancer, psoriasis, gynecologic and inflammatory diseases. The intended audience is composed of clinicians involved in the care of patients suffering from oncologic, gynecologic, rheumatic diseases as well as scientists involved in research into the pathogenesis and treatment of these diseases. This book is unique in that it provides a single, state-of-the-art source for information regarding the mechanism and use of methotrexate in many different areas of medicine.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Methotrexate its mechanism of action in malignant disease and mechanisms of resistance by malignant cells
Current use of methotrexate in the treatment of malignancies in adults
The use of methotrexate in the treatment of childhood malignancies
The mechanisms of methotrexates action in the treatment of inflammatory disease
Other editions - View all
activity acute lymphoblastic leukemia adenosine agents Alarcón GS aminopterin antifolate Arth Rheum Arthritis Rheum associated Bertino JR biochemical Biol Chem blasts blood Cancer Res cell lines cellular chemotherapy cisplatin Clin Oncol clinical corticosteroids cutaneous cytokines decreased dermatomyositis DHFR dihydrofolate reductase disease dose of methotrexate drug ectopic pregnancy effects of methotrexate efficacy enzyme folate folic acid FPGS gamma-glutamyl hydrolase gene high dose high-dose methotrexate human increased inflammatory inhibitor inhibits intrathecal Kamen BA leucovorin leukemia cells levels low dose methotrexate low-dose lymphocytic lymphoma malignant mercaptopurine metabolism metho methotrexate in rheumatoid methotrexate treatment MTX polyglutamates MTX resistance neutrophils nodulosis osteosarcoma Pancytopenia patients treated patients with rheumatoid pediatric protein psoriasis receptors reduced folate carrier regimen reported resistance to MTX Rheum rheumatoid arthritis patients rheumatoid factor Rheumatol 20 sarcoma serum studies synthesis systemic therapeutic therapy for rheumatoid tissue toxicity transport treated with methotrexate treatment of rheumatoid trial tubal tumors vitro